Amanda J. Redig, Ph.D.
Affiliations: | 2009 | Integrated Graduate Program in the Life Sciences | Northwestern University, Evanston, IL |
Area:
Molecular BiologyGoogle:
"Amanda Redig"Parents
Sign in to add mentor| Leonidas C. Platanias | grad student | 2009 | Northwestern | |
| (The protein kinase C (PKC) family and the regulation of hematopoiesis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Guerra SL, Maertens O, Kuzmickas R, et al. (2020) A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Cancer Cell |
| Oxnard GR, Hu Y, Mileham KF, et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. Jama Oncology |
| Bahcall M, Awad MM, Sholl LM, et al. (2018) Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Awad MM, Bahcall M, Sholl LM, et al. (2018) Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 36: 9069-9069 |
| Köhler J, Gokhale PC, Li J, et al. (2018) Abstract 5467: Efficacy of the ERK inhibitor LY3214996 and the PI3K/mTOR inhibitor LY3023414 in patient-derived RAS-mutant NSCLC models Cancer Research. 78: 5467-5467 |
| Redig AJ. (2017) Raising the bar: the future of EGFR inhibition in non-small lung cancer. Translational Lung Cancer Research. 6: S58-S61 |
| Krall EB, Wang B, Munoz DM, et al. (2017) Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 6 |
| Kosaka T, Tanizaki J, Paranal R, et al. (2017) Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors. Cancer Research |
| Krall EB, Wang B, Munoz DM, et al. (2017) KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 6 |
| Krall EB, Wang B, Munoz DM, et al. (2017) Author response: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer Elife |